Janux Therapeutics
JANX
30 hedge funds and large institutions have $614M invested in Janux Therapeutics in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
62.01% more ownership
Funds ownership: 0% → 62.01% (+62%)
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$193M |
| 2 |
O
OrbiMed
New York
|
+$77.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$59.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$42M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.1M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $32K | +$29K | +1,300 | New |
|
27
JP Morgan Chase
New York
| $16K | +$14.4K | +646 | New |
|
28
UBS Group
Zurich,
Switzerland
| $9K | +$7.86K | +353 | New |
|
29
Morgan Stanley
New York
| $2K | +$2.23K | +100 | New |
|
30
US Bancorp
Minneapolis,
Minnesota
| – | +$156 | +7 | New |
|
JANX Hedge Fund Activity: Q2 2021 in Review
30 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2021, worth a combined $614M.
Buyers outnumbered sellers: 30 funds opened new JANX positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $193M.
- 30 institutional investors held Janux Therapeutics (JANX) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $614M of Janux Therapeutics stock for Q2 2021.
- 30 funds opened new Janux Therapeutics positions in Q2 2021 and 0 closed out, a net change of +30 holders.
- The largest Janux Therapeutics buyer in Q2 2021 was RA Capital Management, an estimated $193M added.
Based on aggregated 13F filings for Q2 2021.